Drug Development Program
Noxopharm is running two programs aiming at extending its future oncology drug pipeline. Both programs are well advanced, with selected lead compounds currently undergoing extensive preclinical testing. The two indications targeted by the Company are pancreatic cancer and glioblastoma, both conditions with unmet needs and global significance.
Noxopharm’s lead compound is currently undergoing its last phase of preclinical development and is expected to initiate clinical development stage in mid-2022.
Pancreatic cancer is one of the cancers most likely to result in death, with an overall 5 year survival rate of about 10%. Researchers estimate that the burden of pancreatic cancer may double in the next 40 years.[i]
Glioblastoma multiforme (GBM) is the most common and most aggressive brain tumour, it accounts for more than 60% of brain tumours in adults.[ii] It is the most aggressive brain tumour with a median survival of fourteen to fifteen months from diagnosis.
Based on an innovative mechanism of action aiming at blocking glutamate driven GBM proliferation, selected compounds are currently undergoing extensive screening processes.
Noxopharm anticipates starting the last phase of the lead compound preclinical development toward the end of 2021, with the aim of its drug reaching clinical development phase in 2023.
[i] Lippi G, Mattiuzzi C. The global burden of pancreatic cancer. Arch Med Sci. 2020 May 4;16(4):820-824. doi: 10.5114/aoms.2020.94845
[ii] Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017 Jan 1;18(1):3-9. doi: 10.22034/APJCP.2017.18.1.3
Veyonda® is currently not approved in Australia or any other country